Study of the Efficacy and Safety of a Bispecific Antibody, Teclistamab in Severe Rapidly Progressive Interstitial Lung Disease Associated With Anti-MDA5
Clinical trial NCT07631208 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07631208
- Sponsor
- Assistance Publique - Hôpitaux de Paris
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-10-30
- Primary completion
- 2027-01-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.